When your CAR-T therapy advances to manufacturing, successful scale out for autologous or scale up for allogeneic production and delivery of the therapy to patients requires:
- Determining and executing a manufacturing control strategy to ensure every run adheres to specifications
- Automating the manufacturing process to eliminate human error, reduce manual labor, and lower cost of goods (COGs)
- Employing remote manufacturing to further reduce manual labor and COGs as well as to offer flexibility
- Leveraging assured supply of consumables for robust, consistent production
Sartorius T-Cell Manufacturing Solutions enable robust manufacturing processes to deliver consistent, high-quality CAR-T therapies while lowering COGs.